You are on Trendlyne United States. Click here to go to India website or make United States as your default

Alumis Inc. XNAS: ALMS

Alumis Inc. Live Share Price Today, Share Analysis and Chart

5.00 -0.07 (-1.38%)

63.05% Fall from 52W High

287.3K XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Board Meeting
The next board meeting for Alumis Inc. is on 30 Apr 2025 for the purpose of Alumis Inc Annual General Meeting for 2024 See details
Not Eligible
-
Expensive Valuation
12.5 / 100
Technically Bearish
29.8 / 100

Alumis Inc. Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Alumis Inc. Stock Analysis

Alumis Inc. stock analysis with key metrics, changes, and trends.

Alumis Inc. MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$294.23 M89.84%negative

Annual Net Profit fell 89.84% in the last year to $294.23 M. Its sector's average net profit growth for the last fiscal year was -0.85%.

Price to Earning Ratio-0.92-negative

Price to Earning Ratio is -0.92, which is negative.

Stock Price$5.00-22.84%negative

Stock Price fell 22.84% underperformed its sector by 24.4% in the past week.

Quarterly Net profit$94.76 M141.12%negative

Quarterly Net profit fell 141.12% YoY to $94.76 M. Its sector's average net profit growth YoY for the quarter was 14.79%.

Debt to Equity Ratio0.12-positive

Debt to Equity Ratio of 0.12 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Mutual Fund Holding8.76 %0.8%positive

Mutual Fund Holding increased by 0.8% in the last quarter to 8.76.

Institutional Holding54.44 %0.01%positive

Institutional Holding increased by 0.01% in the last quarter to 54.44.

VIEW LESS


Loading data..

Alumis Inc. - Company Profile

What does Alumis Inc. do?

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

Alumis Inc. Management structure

All Gross Remunerations are in USD
Mr. Martin Babler
Chairman of the Board, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. John R. Schroer
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year

Alumis Inc. Board of directors

All Gross Remunerations are in USD
Mr. Patrick C. Machado, J.D.
Independent Director
-
2024
Gross Remuneration
Year
Dr. James B. Tananbaum,M.D.
Independent Director
-
2024
Gross Remuneration
Year
Mr. Martin Babler
Chairman of the Board, President and Chief Executi
-
2024
Gross Remuneration
Year
Dr. Alan B. Colowick, M.D.,M.P.H.
Independent Director
-
2024
Gross Remuneration
Year
Dr. Srinivas Akkaraju, M.D.,PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Sapna Srivastava, PhD
Independent Director
-
2024
Gross Remuneration
Year

Alumis Inc. FAQ

How is Alumis Inc. today?
Alumis Inc. today is trading in the red, and is down by -1.38% at 5.00.
Alumis Inc. is currently trading down -1.38% on an intraday basis. In the past week the stock fell -22.84%. stock has been down -34.73% in the past quarter and fell None% in the past year. You can view this in the overview section.